-+ 0.00%
-+ 0.00%
-+ 0.00%

BioRestorative Therapies Presents Preliminary Phase 2 BRTX-100 Data At ISCT 2025 Annual Meeting

Benzinga·05/13/2025 13:17:55
Listen to the news

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease ("cLDD") enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy ("ISCT") 2025 Annual Meeting.

No serious adverse events (SAEs) were reported, and there was no dose (40X106 cells) limiting toxicity at 26-104 weeks.